Gavin Gist, APRN
Acute Care · Oxford, MSNPI 1952574048
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,225 of the $42,189 with a category attached, or 74.0%. Johnson & Johnson accounts for 91.3% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $28,285 and has fallen 96.8% since, to $910 in 2025. Among acute care clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 175 payments — averaging $241.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$39K
- Medtronic$1K
- Merck$657
- AstraZeneca$473
- Impulse Dynamics (USA) Inc.$345
- Edwards Lifesciences$224
- plus $788 from 14 others
What the payments were for
- Consulting fees$6001%
- Speaking & faculty fees$31,22574%
- Travel & lodging$6,05014%
- Food & beverage$4,30410%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 67 | $38,520 |
| Medtronic | 11 | $1,182 |
| Merck | 33 | $657 |
| AstraZeneca | 21 | $473 |
| Impulse Dynamics (USA) Inc. | 8 | $345 |
| Edwards Lifesciences | 2 | $224 |
| Boehringer Ingelheim | 6 | $121 |
| E.r. Squibb & Sons, L.L.C. | 1 | $98 |
| Alnylam Pharmaceuticals Inc. | 1 | $94 |
| Novartis | 4 | $81 |
| Bayer | 3 | $69 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $67 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Amgen | 3 | $53 |
| Baxter Healthcare | 2 | $38 |
| Pfizer | 2 | $37 |
| Bardy Diagnostics, Inc. | 2 | $30 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Bridgebio Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$37,452
- OPTIMIZER$385
- Micra$350
- COBALT DR MRI SURESCAN$112
How this compares
$42,189 in reported general payments places this provider in the 95th percentile of 223 acute care providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 624 | $619,842 |
| XareltoRivaroxaban | 452 | $449,804 |
| JardianceEmpagliflozin | 380 | $357,664 |
| FarxigaDapagliflozin Propanediol | 385 | $333,842 |
| EliquisApixaban | 274 | $205,933 |
| Repatha SureclickEvolocumab | 81 | $45,700 |
| BrilintaTicagrelor | 28 | $18,258 |
| VeltassaPatiromer Calcium Sorbitex | 15 | $17,211 |
| Praluent PenAlirocumab | 28 | $14,063 |
| OzempicSemaglutide | 13 | $13,203 |
| Isosorbide Dinitrate | 161 | $12,081 |
| VascepaIcosapent Ethyl | 16 | $8,692 |
| Ranolazine ErRanolazine | 147 | $7,771 |
| Metoprolol Succinate | 679 | $7,656 |
| Atorvastatin Calcium | 862 | $6,520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $81 | $619,842624 claims |
| Johnson & JohnsonXarelto | $38,520 | $449,804452 claims |
| Boehringer IngelheimJardiance | $121 | $357,664380 claims |
| AstraZenecaFarxiga, Brilinta | $473 | $352,100413 claims |
| PfizerEliquis | $37 | $205,933274 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 acute care providers in Mississippi.
Other acute care in Oxford
- Sharon UptonOxford$10K
- Raquel VaughanOxford$6K
- Lee FergusonOxford$5K
- Jene SmithOxford$3K
- Christopher BellTupelo$348K
- Kathleen ArnoldOcean Springs$217K
- Jamie DamicoOcean Springs$17K
- Dylan BoydHattiesburg$15K
- Melinda ClarkStarkville$14K
- Michelle TaylorGulfport$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.